Raloxifene/Vitamin D Combination Therapy Vs. Raloxifene Monotherapy on Serum 25-Hydroxy-Vitamin D Level Among Postmenopausal Women with Osteoporosis or Osteopenia: A Randomized Controlled Trial

Overview

Journal J Bone Metab

Date 2022 Sep 26

PMID 36153851

Authors

You-Bin Lee

Ki-Hyun Baek

Ho Yeon Chung

Dong-Won Byun

Yong-Ki Min

Affiliations

Soon will be listed here.

Abstract

Background: We compared the efficacy of a fixed dose combination of raloxifene 60 mg/vitamin D 800 IU to raloxifene 60 mg alone on vitamin D status, as indicated by change in serum 25-hydroxy-vitamin D (25[OH]D) levels.

Methods: In this 16-week, open-label, randomized, active controlled, multicenter clinical trial conducted in 4 university-affiliated hospitals in Korea, postmenopausal women aged 55 to 70 years with osteoporosis or osteopenia were randomly assigned in a 1:1 ratio to receive raloxifene 60 mg/cholecalciferol 800 IU combination therapy or raloxifene 60 mg monotherapy. Primary endpoint was change in serum 25(OH)D level from baseline to 16 weeks after the intervention.

Results: A total of 96 participants were randomly assigned to raloxifene/vitamin D combination therapy (N=49) and raloxifene monotherapy (N=47) groups. At week 16, serum 25(OH)D level increased from baseline, only in the raloxifene/vitamin D combination therapy group. Change in serum 25(OH)D level from baseline to week 16 was higher in the raloxifene/vitamin D combination therapy group (2.7±6.5 ng/mL) than in the raloxifene monotherapy (-1.7±6.2 ng/mL; P=0.0034) group. Proportions and number of adverse events (AEs) categorized by the System-Organ Class were not different between the groups. There was only one severe AE case (spondylolisthesis; raloxifene/vitamin D group), unlikely to be related to trial intervention.

Conclusions: Among postmenopausal women with osteoporosis or osteopenia, a fixed dose combination of raloxifene 60 mg/vitamin D 800 IU showed superior efficacy in elevating serum 25(OH)D levels compared with raloxifene 60 mg alone during 16 weeks of follow-up. The safety of raloxifene/vitamin D combination was comparable to raloxifene alone.

References

Kim K, Min Y, Koh J, Chung Y, Kim K, Byun D . Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial. Yonsei Med J. 2014; 55(3):715-24. PMC: 3990072. DOI: 10.3349/ymj.2014.55.3.715. View

Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020; 26(Suppl 1):1-46. DOI: 10.4158/GL-2020-0524SUPPL. View

Didriksen A, Grimnes G, Hutchinson M, Kjaergaard M, Svartberg J, Joakimsen R . The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels. Eur J Endocrinol. 2013; 169(5):559-67. DOI: 10.1530/EJE-13-0233. View

Delmas P, Ensrud K, Adachi J, Harper K, Sarkar S, Gennari C . Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002; 87(8):3609-17. DOI: 10.1210/jcem.87.8.8750. View

Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore C . Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2008; 20(2):239-44. DOI: 10.1007/s00198-008-0650-y. View

Eastell R, Rosen C, Black D, Cheung A, Murad M, Shoback D . Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019; 104(5):1595-1622. DOI: 10.1210/jc.2019-00221. View

Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A . Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int. 2003; 14(10):793-800. DOI: 10.1007/s00198-003-1424-1. View

Lips P, Hosking D, Lippuner K, Norquist J, Wehren L, Maalouf G . The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med. 2006; 260(3):245-54. DOI: 10.1111/j.1365-2796.2006.01685.x. View

Choi H, Min Y, Byun D, Hahn M, Kim K, Kim B . Korean Society for Bone and Mineral Research Task Force Report: Perspectives on Intermittent High-dose Vitamin D Supplementation. J Bone Metab. 2017; 24(3):141-145. PMC: 5613018. DOI: 10.11005/jbm.2017.24.3.141. View

10.

Kim K, Choi H, Choi M, Chung H . Calcium and Vitamin D Supplementations: 2015 Position Statement of the Korean Society for Bone and Mineral Research. J Bone Metab. 2015; 22(4):143-9. PMC: 4691588. DOI: 10.11005/jbm.2015.22.4.143. View

11.

Gorai I, Hattori S, Tanaka Y, Iwaoki Y . Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab. 2011; 30(3):349-58. DOI: 10.1007/s00774-011-0325-1. View

12.

Lee H, Kang W, Jung W, Gwon M, Cho K, Lee B . Pharmacokinetic Drug Interaction Between Raloxifene and Cholecalciferol in Healthy Volunteers. Clin Pharmacol Drug Dev. 2022; 11(5):623-631. PMC: 9305550. DOI: 10.1002/cpdd.1062. View

13.

Lee C, Kim S, Suh W, Kim J, Jung J, Yoon S . The Effect of Education and Vitamin D Supplementation on the Achievement of Optimal Vitamin D Level in Korean Postmenopausal Women. J Bone Metab. 2019; 26(3):193-199. PMC: 6746667. DOI: 10.11005/jbm.2019.26.3.193. View

14.

Lim S, Kung A, Sompongse S, Soontrapa S, Tsai K . Vitamin D inadequacy in postmenopausal women in Eastern Asia. Curr Med Res Opin. 2007; 24(1):99-106. DOI: 10.1185/030079908x253429. View

15.

Meunier P, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S . Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int. 2000; 10(4):330-6. DOI: 10.1007/s001980050236. View

16.

Gambacciani M . Selective estrogen modulators in menopause. Minerva Ginecol. 2013; 65(6):621-30. View

17.

Holick M, Chen T . Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008; 87(4):1080S-6S. DOI: 10.1093/ajcn/87.4.1080S. View

18.

Autier P, Gandini S, Mullie P . A systematic review: influence of vitamin D supplementation on serum 25-hydroxyvitamin D concentration. J Clin Endocrinol Metab. 2012; 97(8):2606-13. DOI: 10.1210/jc.2012-1238. View

19.

Clemett D, Spencer C . Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs. 2000; 60(2):379-411. DOI: 10.2165/00003495-200060020-00013. View